Investing in China’s Pharmaceutical Industry is the second edition of a paper published by PricewaterhouseCoopers looking into the current pharmaceutical market conditions in China.

The report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical (pharma) industry in China. Building on the foundation set in the first report, published in 2006, this new edition includes six additional key areas, and reviews, updates and expands the different aspects discussed at that time.

By the time of this publication, three years will have elapsed since our previous report, and the pharmaceutical landscape globally and in China has evolved, the globalisation of the sector has continued, and regulations have changed.

After a waiting period of two years, on October 14th, 2008, the Chinese government released the draft of the healthcare reform plan under the official name, “Opinions on Deepening Pharmaceutical and Health System Reform (Draft),” for public comments.

While this document offers limited details on the roadmap for the future of healthcare, it does provide clear statements on the high-level principles and objectives of China’s new healthcare systems. In the coming years, multiple topics discussed in this paper will be significantly influenced by this healthcare reform plan.

Chapter 1 focuses on the characteristics of the Traditional Chinese Medicine (TCM) market, while Chapter 2 estimates the growth potential for the Chinese Over The Counter (OTC) market.

The medical devices sector is presenting a viable business opportunity for both domestic and multinational companies. Chapter 3 provides an overview of the current market size and trends in this fast-growing industry. ...

Download Investing in China’s Pharmaceutical Industry, 2nd Edition

PDF format, 945KB, 38Pages.

CONTENTS
Introduction 2
Chapter 1
Traditional Chinese Medicine, The Origin of Modern Medicine:
Where Is It Now? 4
Chapter 2
East Meets West in the OTC Market 5
Chapter 3
Medical Devices – A Market of Opportunities 6
Chapter 4
Contract Research Organisations Benefit from
Pharma Moving Up the Value Chain 8
Chapter 5
Contract Manufacturing Organisations Going Strong 11
Chapter 6
Building An Innovation-Oriented Country Through Pharma R&D 12
Chapter 7
Tax Incentives Support China In Becoming A World R&D Base 14
Chapter 8
Navigating the Risks of Bribery and Corruption in Sales and Marketing 15
Chapter 9
Cutting Drug Prices: Whom Does It Help? 17
Chapter 10
Risks and Challenges of A Complex Distribution System 18
Chapter 11
Intellectual Property Protection: Is It Getting Better? 20
Chapter 12
The Pharma Sector: A Front-Runner in Consolidation 22
Chapter 13
Capital Markets and Financial Reporting: What To Consider? 25
Conclusion – Looking Forward 27

Comments (1)

Name

Email

Comment

smaller | bigger

Add Comment